Exelixis (EXEL)
(Delayed Data from NSDQ)
$22.40 USD
-0.15 (-0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 61 - 80 ( 182 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Cabo Successor XL092 Enters Broad Clinical Development Program With Ipi/Nivo +/- Bempeg; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
COSMIC 312 Data in 1L HCC Presented at ESMO Asia; XL092 Will Likely Carry the Torch; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis Reports Surprising 3Q21 Cabometyx Revenue Miss, Trimming Estimates, Lowering PT from $65 to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis Strikes STORM Partnership and In-Licenses XL114 from Aurigene
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
ESMO and post-FDA updates on COSMIC-021 Trial Data in mCRPC
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
The Best is Yet to Come for Exelixis; Fireside Chat with CEO Michael Morrissey; Reiterate Buy Rating and $65 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Momentum Builds for Exelixis on Japanese Approval and ESMO 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis and Invenra Expand Collaboration to Include Additional Oncology Antibody Targets
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
A Beat and Raise for Exelixis-Still More to Come from Cabozantinib; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Our Prelude to Exelixis 2Q21 Earnings; Reiterate Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department